Does Added Objective Tremor Monitoring Improve Clinical Outcomes in Essential Tremor Treatment? / Vittal, Padmaja; Pulliam, Christopher L.; Goetz, Christopher G.; Ouyang, Bichun; Jankovic, Joseph; Ramirez-Castaneda, Juan L.; Heldman, Dustin A.In: Movement Disorders Clinical Practice, Vol. 5, No. 1, 01.01.2018, p. 96-98.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Does Added Objective Tremor Monitoring Improve Clinical Outcomes in Essential Tremor Treatment?
AU - Vittal, Padmaja
AU - Pulliam, Christopher L.
AU - Goetz, Christopher G.
AU - Ouyang, Bichun
AU - Jankovic, Joseph
AU - Ramirez-Castaneda, Juan L.
AU - Heldman, Dustin A.
N1 - Funding Information: The Rush Parkinson’s Disease and Movement Disorder program is supported by funds received as a designated Parkinson’s Disease Foundation Parkinson Research Center and a National Parkinson Foundation Center of Excellence. The Baylor College of Medicine Parkinson’s Disease Center and Movement Disorders Clinic is supported by funds received as a designated Parkinson’s Disease Foundation Parkinson Research Center and a National Parkinson Foundation Center of Excellence. Funding Information: Ethical Compliance Statement: We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Funding Sources and Conflict of Interest: The research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Number R44AG034708. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Drs. Heldman and Pulliam received compensation from Great Lakes NeuroTechnologies for employment. The authors report no sources of funding and no conflicts of interest. Financial Disclosures for the previous 12 months: Padmaja Vittal was the recipient of the Clinical Research Training Fellowship grant in Ataxia sponsored by the American Brain Foundation and the National Ataxia Foundation and has received honoraria from Teva Pharmaceutical Industries Ltd. Dustin A. Heldman and Christopher L. Pulliam have received compensation from Great Lakes NeuroTechnologies as employees. Christopher G. Goetz has received consulting/Advisory Board membership honoraria from Acadia, Addex, Avanir, Boston Scientific, Neurocrine, Oxford Biomedica, WebMD; honoraria from Oregon Health and Science University; royalties from Elsevier Publishers, Oxford University Press, and Wolters Kluwer; and has received research/training grants for funding to Rush University Medical Center from the National Institutes of Health, the Michael J. Fox Foundation for Parkinson Research, the Parkinson’s Disease Foundation (for directing the Movement Disorders Fellowship Program), and the International Parkinson and Movement Disorder Society (for directing the translation program for the MDS-UPDRS and the Unified Dystonia Rating Scale). Joseph Jankovic has received research and/or training grants from Adamas Pharmaceuticals, Inc.; Allergan, Inc.; Biotie Therapies; CHDI Foundation; Civitas/ Acorda Therapeutics; the Dystonia Medical Research Foundation; the Huntington Study Group; Kyowa Haako Kirin Pharma, Inc.; Lundbeck Inc.; Medtronic Neuromodulation; Merz Pharmaceuticals; the Michael J. Fox Foundation for Parkinson Research; the National Institutes of Health; Neurocrine Biosciences; NeuroDerm Ltd.; the Parkinson’s Foundation; the Parkinson Study Group; Pfizer; Prothena Biosciences Inc.; Psyadon Pharmaceuticals, Inc.; Revance Therapeutics, Inc.; Sangamo BioSciences, Inc.; St. Jude Medical; Teva Pharmaceutical Industries Ltd.; in addition, he has served as a consultant or as an advisory committee member for Adamas Pharmaceuticals, Inc.; Allergan, Inc.; Pfizer Inc.; Revance Therapeutics, Inc.; Teva Pharmaceutical Industries Ltd.; has received royalties or other payments from Cambridge, Elsevier, Future Science Group, Hodder Arnold, MedLink, Neurology, Lippincott Williams and Wilkins, and Wiley-Blackwell; and has served on editorial boards for Expert Review of Neurotherapeutics; MedLink; Neurology in Clinical Practice; The Botulinum Journal; PeerJ; Therapeutic Advances in Neurological Disorders; Neurotherapeutics; Tremor and Other Hyperkinetic Movements; the Journal of Parkinson’s Disease; and UpToDate. Juan L. Ramirez-Castaneda has nothing to disclose.
PY - 2018/1/1
Y1 - 2018/1/1
UR - http://www.scopus.com/inward/record.url?scp=85067219000&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067219000&partnerID=8YFLogxK
U2 - 10.1002/mdc3.12554
DO - 10.1002/mdc3.12554
M3 - Letter
AN - SCOPUS:85067219000
VL - 5
SP - 96
EP - 98
JO - Movement Disorders Clinical Practice
JF - Movement Disorders Clinical Practice
SN - 2330-1619
IS - 1